EGS 21

Drug Profile

EGS 21

Alternative Names: EGS21

Latest Information Update: 13 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Enzo Biochem
  • Class Glycolipids; Small molecules
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Crohn's disease; Non-alcoholic steatohepatitis

Most Recent Events

  • 13 Aug 2015 Phase II development is ongoing in Israel
  • 14 Oct 2006 Phase-II clinical trials in Non-alcoholic steatohepatitis in Israel (unspecified route)
  • 16 Mar 2006 Phase-II clinical trials in Crohn's disease in Israel (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top